Flag of the European Union EU Clinical Trials Register Help

Clinical trials for C-terminal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: C-terminal. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-002373-22 Sponsor Protocol Number: 2012-NIGRAM-VUMC-001 Start Date*: 2014-05-12
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: ThE SoF-Trial (SoFT) - The Effect of Sevelamer on FGF23 Trial - A clinical trial assessing the quantitative effect of phosphate binding therapy on FGF23.
    Medical condition: cardiovascular disease in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011883-12 Sponsor Protocol Number: I2Y-MC-GHFA(c) Start Date*: 2009-08-26
    Sponsor Name:Elli Lilly and Company
    Full Title: A Phase 2 Study for Transdermal Application of Teriparatide
    Medical condition: Treatment of osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005999-13 Sponsor Protocol Number: D8180C00034 Start Date*: 2008-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease ...
    Medical condition: Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004513-15 Sponsor Protocol Number: Start Date*: 2005-11-28
    Sponsor Name:Univ. Prof. Dr. Christoph Zielinski
    Full Title: ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE
    Medical condition: Metastatic bone disease due to breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002648-10 Sponsor Protocol Number: ADDI-D Start Date*: 2014-03-04
    Sponsor Name:Bruno Farmaceutici S.p.a.
    Full Title: THE EFFECT OF A DAILY AND WEEKLY ADMINISTRATION OF DIFFERENT DOSES OF CALCIDIOL ON 25(OH)D3 SERUM LEVELS AND ON MINERAL AND BONE METABOLIC MARKERS IN POSTMENOPAUSAL FEMALE SUBJECTS OVER 55 YEARS OF...
    Medical condition: Postmenopausal female subjects with inadequate levels or deficit of 25(OH)D3
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003570-11 Sponsor Protocol Number: BC-6072 Start Date*: 2019-10-21
    Sponsor Name:Ghent University Hospital
    Full Title: The use of buffered soluble alendronate 70 mg (Steovess/Binosto) after denosumab discontinuation to prevent increase in bone turnover.
    Medical condition: erosive osteoarthritis of the interphalangeal finger joints
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10016686 Finger osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006224-21 Sponsor Protocol Number: IJB-BCTL-20119167 Start Date*: 2013-06-20
    Sponsor Name:Jules Bordet Institute
    Full Title: A pre-operative window study evaluating Denosumab, a RANK-Ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer
    Medical condition: We have designed this study to investigate if denosumab can modulate a number of biological processes including prolferation, RANK signaling and the mammary stem cell subpopulation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001978-28 Sponsor Protocol Number: IEOS698/312 Start Date*: 2012-11-05
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A Phase II study of intermittent letrozole plus transdermal estradiol gel 3 month-therapy as adjuvant endocrine treatment for postmenopausal women with hormone-receptor positive early stage breas...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006373-33 Sponsor Protocol Number: 1617 Start Date*: 2009-02-11
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: Effect of montelukast on levels of metalloproteinase-9 (MMP-9), MMP-12, tissue inhibitor metalloproteinase-1 (TIMP-1), procollagen peptide type 1 C-terminal (PICP) and TGF-beta1 on induced sputum o...
    Medical condition: Intermittent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004715-22 Sponsor Protocol Number: VX06-702-304 Start Date*: 2006-10-26
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002349-12 Sponsor Protocol Number: RALBAT Start Date*: 2013-08-17
    Sponsor Name:Unit of Infectious Diseases, Department of Medical Scieces, University of Torino c/o ASLTO2, Amedeo di Savoia Hospital
    Full Title: “Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pil...
    Medical condition: HIV infection, osteopenia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007725-46 Sponsor Protocol Number: ASBI 307 Start Date*: 2009-02-06
    Sponsor Name:Asubio Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 We...
    Medical condition: Cachexia associated with chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003638-28 Sponsor Protocol Number: 2015/576 Start Date*: 2015-09-30
    Sponsor Name:Aarhus University Hospital
    Full Title: ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of disconti...
    Medical condition: Rheumatoid arthritis and osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10031289 Osteoporosis, unspecified LLT
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004370-96 Sponsor Protocol Number: LG-TCS-AD Start Date*: 2019-02-15
    Sponsor Name:Jacob Pontoppidan Thyssen
    Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004903-15 Sponsor Protocol Number: 2020-004903-15 Start Date*: 2022-04-20
    Sponsor Name:University of Alabama at Birmingham
    Full Title: Denosumab (DMAB) Discontinuation and Switching Study in Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
    Medical condition: Glucocorticoid-Induced Osteoporosis (GIOP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020872-49 Sponsor Protocol Number: PI10-Pr.CHOUKROUN-FRENCH Start Date*: 2013-04-18
    Sponsor Name:CHU Amiens
    Full Title: Étude randomisée, en double aveugle, versus placebo, évaluant chez des patients porteurs d'une MRC, non dialysés, l'effet du traitement par carbonate de sevelamer sur le contrôle des taux sériques ...
    Medical condition: Maladies Rénales Chroniques au stade 3b et 4 (DFG compris entre 15 et 45 ml/min)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003230-26 Sponsor Protocol Number: MIV-711-201 Start Date*: 2016-03-23
    Sponsor Name:Medivir AB
    Full Title: A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis
    Medical condition: Knee Joint Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003774-16 Sponsor Protocol Number: EIFFEL Start Date*: 2016-06-07
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases
    Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001284-40 Sponsor Protocol Number: 160315 Start Date*: 2015-05-20
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of liraglutide on bone turnover, bone mass and bone cell function
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 00:03:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA